FY25 global sales exceed projection, up 49% on prior year
Filed with ASX · · 2 pages · English
Earlier from Immuron
- Immuron Travelan® highest sales in history
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan continued strong sales growth
- Immuron Announces Travelan Clinical Trial Update
Later from Immuron
- Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
- Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream
- Immuron partners with InvestorHub
- Appendix 4E Preliminary Final Report
- FY25 Results Presentation
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron